ZYBT (Zhengye Biotechnology) Earnings growth in current year

Corporate emblem and logo of Zhengye Corp (ZYBT)

The annual growth rate of earnings per share demonstrates the impact of Zhengye Biotechnology (ZYBT) owning high-tech vaccine production plants in China. However, aggressive consolidation of the local agricultural market and price dumping are creating pressure. Strategic outsourcing of packaging and raw materials ensures margin stability. Meanwhile, the 0.00 level serves as a critical benchmark, signaling a gradual achievement of market consensus regarding the revenue valuation of Zhengye Biotechnology (ZYBT).

ZYBT: Jilin Zhengye Biotechnology Net earnings per share growth this year 01/08/2025 - 11/17/2026

Financial and market metric breakdowns for Zhengye Corp (ZYBT)

Fundamental valuation:ZYBT, Zhengye Bio
Flagship merchandise of Zhengye Bio

Steady demand for veterinary biologicals from Zhengye Biotechnology (ZYBT) allows investors to track the effectiveness of monetizing professional trust among farmers through the annual earnings per share (EPS) growth profile. This indicator measures the percentage deviation of current net income per share from the previous year's values, enabling investors to verify the sustainability of the yield trend and promptly recognize a shift in the economic cycle phase.